John Overdeck’s Insys Therapeutics, Inc. INSY Stock Holding History

John Overdeck’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-44,700	Closed	-$156K	–	3645
2018 Q4	$156K	Buy	+44,700	New	+$311K	﹤0.01%	2762
2017 Q1	–	Sell	-79,777	Closed	-$734K	–	3512
2016 Q4	$734K	Sell	79,777 -75,037	-48%	-$848K	﹤0.01%	2234
2016 Q3	$1.82M	Buy	154,814 +64,628	+72%	+$982K	0.01%	1532
2016 Q2	$1.17M	Sell	90,186 -272,177	-75%	-$3.97M	0.01%	1619
2016 Q1	$5.79M	Buy	362,363 +90,609	+33%	+$1.72M	0.03%	648
2015 Q4	$7.78M	Buy	+271,754	New	+$7.53M	0.04%	512
2015 Q3	–	Sell	-191,095	Closed	-$6.86M	–	2972
2015 Q2	$6.86M	Buy	+191,095	New	+$5.95M	0.03%	581
2014 Q2	–	Sell	-194,114	Closed	-$4.02M	–	2446
2014 Q1	$4.02M	Buy	+194,114	New	+$3.85M	0.02%	711
2013 Q4	–	Sell	-33,552	Closed	-$391K	–	2468
2013 Q3	$391K	Buy	+33,552	New	+$275K	﹤0.01%	1393

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

John Overdeck's INSY Position: Q1 2019 in Review

John Overdeck sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 44,700 shares — an estimated $156K sold.

John Overdeck first reported a position in INSY in Q3 2013 and held it in 9 quarters. The position peaked at $7.78M in Q4 2015. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

John Overdeck reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
John Overdeck sold 44,700 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $156K.
John Overdeck first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 9 quarters.
John Overdeck's Insys Therapeutics, Inc. position peaked at $7.78M in Q4 2015.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Two Sigma Investments's 13F filing for Q1 2019, filed 15 May 2019.